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Aspergillus fumigatus infections are associated with a high mortality rate for immu-
nocompromised patients. The complement system is considered to be important in 
protection against this fungus, yet the course of activation is unclear. The aim of this 
study was to unravel the role of the classical, lectin, and alternative pathways under 
both immunocompetent and immunocompromised conditions to provide a relevant 
dual- perspective on the response against A. fumigatus. Conidia (spores) from a clinical 
isolate of A. fumigatus were combined with various human serum types (including serum 
deficient of various complement components and serum from umbilical cord blood). 
We also combined this with inhibitors against C1q, mannose-binding lectin (MBL), and 
ficolin-2 before complement activation products and phagocytosis were detected by 
flow cytometry. Our results showed that alternative pathway amplified complement on 
A. fumigatus, but required classical and/or lectin pathway for initiation. In normal human 
serum, this initiation came primarily from the classical pathway. However, with a dysfunc-
tional classical pathway (C1q-deficient serum), lectin pathway activated complement 
and mediated opsonophagocytosis through MBL. To model the antibody-decline in a 
compromised immune system, we used serum from normal umbilical cords and found 
MBL to be the key complement initiator. In another set of experiments, serum from 
patients with different kinds of immunoglobulin insufficiencies showed that the MBL 
lectin pathway contribution was highest in the samples with the lowest IgG/IgM binding. 
In conclusion, lectin pathway appears to be the primary route of complement activation 
in the absence of anti-A. fumigatus antibodies, whereas in a balanced immune state 
classical pathway is the main activator. This suggests a crucial role for the lectin pathway 
in innate immune protection against A. fumigatus in immunocompromised patients.
Keywords: complement, lectin pathway, MBl, igM, Aspergillus fumigatus, immunocompromised
Abbreviations: IPA, invasive pulmonary aspergillosis; mAb, monoclonal antibody; MBL, mannose-binding lectin; MFI, mean 
fluorescence intensity; NHS, normal human serum; pAb, polyclonal antibody; PRM, pattern-recognition molecule; UCS, 
umbilical cord serum.
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inTrODUcTiOn
The fungus Aspergillus fumigatus has its natural habitat in soil 
where it decomposes organic debris and the fungus is usually 
non-pathogenic for immunocompetent humans. However, 
immunocompromised patients are highly susceptible to pulmo-
nary invasion – a disease termed invasive pulmonary aspergillosis 
(IPA). IPA can turn into systemic dissemination when conidia 
(spores) mature into fungal hyphae breaching the pulmonary 
epithelia and reaching the blood stream. This exposes other 
organs like kidney, heart, and brain to fungal attack (1). With a 
mortality rate of 40–90%, IPA poses a serious threat to several 
patient groups suffering from immune demolishing diseases such 
as leukemia and AIDS or during immunosuppressive therapy 
used under organ transplantations (2).
Due to the small airborne conidia (2–3 μm), A. fumigatus is 
able to penetrate into the alveolar spaces and initiate an infection. 
The conidia are constantly present in our daily surroundings and 
exposure is practically inevitable (1). Azole-based drugs are com-
monly used as prophylaxis and treatment against A. fumigatus 
infections, but resistant strains of A. fumigatus are emerging, 
possibly due to agricultural use of azole-fungicides (3, 4). Thus, 
research covering new aspects of the immune response against 
A. fumigatus is important for future treatment alternatives.
As part of the innate immune defense, complement is an 
essential facilitator of opsonophagocytosis of invading patho-
gens. Complement is a system based on pattern-recognition 
molecules (PRMs) and protein cleavage cascades that rapidly 
intensify an anti-pathogenic response. Complement is initiated 
via three pathways: the lectin, the classical, and the alternative 
pathway. The lectin pathway works by direct binding of PRMs, 
named mannose-binding lectin (MBL), ficolins, and collectins, to 
pathogenic surfaces. PRM-associated serine proteases (MASPs) 
cleave C4 and C2, which lead to formation of the C3 convertase 
C4b2a that cleaves C3 into the strong opsonizing factor C3b. 
C1q, the classical pathway PRM, utilizes immunoglobulins as 
adaptors to bind pathogens and associated proteases (C1r/C1s) 
cleave C4 and C2 and mediate activation and deposition of C3b. 
Alternative pathway is activated by spontaneous hydrolysis of 
C3 and moreover works as a C3b-amplification loop. After C3 
cleavage, all pathways unite into the terminal part of the cascade, 
which leads to formation of the lytic terminal complement com-
plex (TCC) (5).
The organization of complement activation on A. fumigatus 
has not been fully elucidated and previous in  vitro studies are 
based on the immunocompetent state. A compromised immune 
system is the leading cause of IPA, and thus we aimed to clarify the 
roles of the three complement pathways on A. fumigatus under 
both immunocompetent and immunocompromised conditions.
MaTerials anD MeThODs
A. fumigatus
The A. fumigatus strain was obtained from a fatal case of IPA 
(a kind gift from Professor Romani from the Infectious Diseases 
Institute of the University of Perugia). A. fumigatus was grown 
on Sabouraud glucose agar with chloramphenicol (89579, 
 Sigma-Aldrich) for 4  days at 37°C before resting conidia were 
harvested in PBS/0.025% Tween 20. Conidia were filtered to 
remove unwanted hyphae and afterward washed extensively 
before heat-inactivation for 15  min at 121°C in PBS. Aliquots 
of conidia were stored at −80°C. Concentrations applied: 
5 × 107 cells/ml for consumption assays and 1 × 107 cells/ml for 
complement activation and phagocytosis assays.
Primary antibodies
For the experiments we used the following in-house produced 
antibodies (Abs): mouse anti-ficolin-2 mAb FCN219 (6) and 
mouse anti-ficolin-1 mAb cross-reacting with ficolin-2 (7). 
Moreover, we applied the following commercial Abs: mouse 
anti-MBL mAb (HYB 131-1, Bioporto Diagnotics, Gentofte, 
Denmark), rabbit anti-C1q pAb (A0136, Dako, Glostrup, 
Denmark), rabbit anti-IgM and anti-IgG pAbs (0425 and 0423, 
Dako), rabbit anti-C4c and -C3c pAbs (0369 and F0201, Dako), 
and mouse anti-TCC mAb clone aE11 (011-01, AntibodyChain, 
Utrecht, Netherlands). The isotype controls included were: 
mouse IgG1κ and IgG2α isotype controls (557273 and 555571, 
BD Biosciences, Albertslund, Denmark) and rabbit IgG isotype 
control (10500C, Invitrogen, Naerum, Denmark).
secondary antibodies
The secondary Abs used for the experiments were: HRP-
conjugated donkey anti-rabbit Ab (NA934V, GE Healthcare, 
Broendby, Denmark), HRP-conjugated rabbit anti-mouse pAb 
(P0260, Dako), HRP-conjugated streptavidin (RPN1231V, GE 
healthcare), FITC-conjugated goat anti-rabbit pAb (F1262, 
Sigma-Aldrich, Copenhagen, Denmark), and FITC-conjugated 
goat anti-mouse pAb (F0479, Dako).
inhibitors
Following specific Abs were used to inhibit the binding of ficolin-2, 
MBL, and C1q to their ligands: in-house produced anti-ficolin-2 
inhibitory mAb FCN212 isotype IgG1 (unpublished), anti-MBL-
inhibitory mAb 3F8 (8), and anti-C1q mAb clone CLB/C1q85 
isotype IgG1 (MW1828, Sanquin, Amsterdam, Netherlands). 
We included mouse IgG1 isotype control (BD Biosciences) and 
anti-MBL mAb 1C10 (8) as mock-inhibitors.
Proteins
Recombinant proteins were expressed and purified as previ-
ously described (9). In short, MBL and ficolin-2 were expressed 
in CHO-DG44 cells cultivated in RPMI 1640 medium 
(Sigma-Aldrich) supplemented with 10% FCS, 100  U/ml 
penicillin, 0.1  mg/ml streptomycin, 2  mM l-glutamine, and 
200 nM methotrexate. Purification was performed with affinity 
chromatography using anti-ficolin mAb FCN219 for ficolin-2 
purification or mannan–agarose for MBL purification. Purified 
C1q (A099) and purified C2 (A112) were purchased from 
CompTech, Tyler, TX, USA.
serum samples
We applied three types of sera previously described from patients 
deficient in one of the following complement components: C2 
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(10), MBL (9), and C1q (11). Moreover, 17 venous blood samples 
and 23 umbilical cord blood samples were collected from healthy 
individuals. Blood was collected in no-additive glass vials, coagu-
lated for 2 h/RT and centrifuged for 10 min at 2000 × g. Serum 
was stored at −80°C until experiments were performed. A normal 
human serum (NHS) pool was prepared from six individuals 
(three male/three female).
Binding of native MBl, Ficolin-2, and c1q 
Measured in Western Blotting
Conidia and NHS with inhibitors/mock-inhibitors were co-
incubated for 1 h at 4°C end-over-end. After extensive washing, 
conidia were eluted with LDS sample buffer, and the total content 
was run on a 4–12% bis-Tris polyacrylamide gel under reducing 
conditions (Life Technologies). rficolin-2 (0.2 μg), rMBL (0.1 μg), 
and purified C1q (0.1 μg) were used as loading controls. Proteins 
were blotted onto polyvinylidene difluoride membranes (GE 
Healthcare) and the membranes were probed with anti-ficolin-1 
mAb FCN106 (cross-react with ficolin-2)/rabbit anti-mouse-
HRP, anti-MBL mAb HYB 131-1/rabbit anti-mouse-HRP, or 
anti-C1q pAb A0136/donkey anti-rabbit-HRP. Membranes were 
developed using SuperSignal West Femto Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL, USA).
complement activation on A. fumigatus 
Measured in Flow cytometry
Activation of complement on A. fumigatus was examined 
under various conditions (see below) and followed the same 
experimental procedure: 107 conidia/ml were incubated in 10% 
human serum for 30 min at 37°C, then washed and stained with 
primary or isotype control Abs followed by FITC-conjugated 
secondary Abs in these combinations: anti-C4c pAb/goat anti-
rabbit-FITC pAb; anti-C3c pAb/goat anti-rabbit-FITC pAb; 
anti-TCC mAb/goat anti-mouse-FITC pAb; rabbit IgG isotype/
goat  anti-rabbit-FITC pAb; and mouse IgG1 isotype/goat anti-
mouse-FITC pAb. Ab staining was performed for 30 min at 4°C, 
and washing-steps were made in the specific assay-suitable dilu-
tion buffer. Deposition and formation of C4b, C3b, and TCC on 
the conidia was measured as mean fluorescence intensity (MFI) 
by flow cytometry (Gallios, Beckman Coulter) and data were 
analyzed using Kaluza software (Beckman Coulter).
TBs/ca2+ and TBs/ca2+/Mg2+ conditions
Complement activation on A. fumigatus was measured after incu-
bation in the NHS pool diluted in either (I) TBS/Ca2+ [10 mM 
Tris–HCl, 150 mM NaCl, 2 mM CaCl2, 1% fetal calf serum heat-
inactivated for 30 min at 56°C (HI-FCS) (pH 7.4)] or (II) TBS/
Ca2+/Mg2+ [TBS, 2 mM CaCl2, 1 mM MgCl2, 1% HI-FCS (pH 7.4)].
eDTa and Mg/egTa conditions
Complement activation on A. fumigatus was measured using 
the NHS pool diluted in the following buffers: (I) barbital 
buffer [5  mM barbital sodium, 145  mM NaCl, 2  mM CaCl2, 
1  mM  MgCl2, 1% HI-FCS (pH 7.4)], (II) EDTA buffer (TBS, 
10  mM EDTA, 1% HI-FCS), or (III) Mg2+/EGTA buffer 
(TBS, 10 mM MgCl2, 10 mM EGTA, 1% HI-FCS).
reconstitution of c2-, MBl-, and  
c1q-Deficient human sera
Aspergillus fumigatus was added into the following sera: (I) 
C2-deficient serum diluted in barbital buffer and reconstituted 
with C2 (10 μg/ml), (II) MBL-deficient serum diluted in TBS/
Ca2+ (to reduce alternative pathway interference) and reconsti-
tuted with MBL (10 μg/ml), and (III) C1q-deficient serum diluted 
in TBS/Ca2+ and reconstituted with C1q (10 μg/ml). Complement 
activation was measured using flow cytometry.
Ficolin-2 and MBl inhibition in  
c1q-Deficient serum
Complement activation on A. fumigatus was measured in 
 C1q-deficient serum, diluted in barbital buffer, using the fol-
lowing inhibitors (5 μg/ml): ficolin-2 inhibitor (FCN212), MBL 
inhibitor (3F8), or MBL mock-inhibitor (1C10).
Opsonophagocytosis
Opsonization and phagocytosis was measured in an assay 
using FITC-conjugated conidia and isolated human neutro-
phils. FITC-conjugation was made by mixing FITC powder 
(F7250, Sigma-Aldrich) and conidia (5 ×  10−8 μg/conidia) for 
30 min end-over-end at room temperature followed by removal 
of unbound FITC by extensive washing. FITC-conjugated 
A. fumigatus conidia (1 × 107/ml) were opsonized for 30 min at 
37°C in 10% C1q-deficient serum including 10 μg/ml of either 
the MBL inhibitor (3F8) or mock-inhibitor (1C10). Opsonized 
conidia were washed and combined with human neutrophils 
isolated with Polymorphprep (Axis-Shield, Oslo, Norway) 
according to the manufacturer’s instructions. Neutrophils and 
conidia co-incubated for 30 min at 37°C in a cell ratio of 1:5. After 
washing the cells and before flow cytometric analysis, 50 μl try-
phan blue was added to quench fluorescence from non-ingested 
conidia. FITC-positive neutrophils were identified by gating. 
Barbital buffer was used as dilution/washing buffer throughout 
the experiment.
We also performed fluorescence and differential interference 
contrast (DIC) imaging of neutrophils phagocytizing FITC-
conjugated A. fumigatus conidia (using the same protocol) to 
get a visual impression of the process. We used Zeiss LSM 700 
Axio Imager 2 with a Plan-Apochromat 63x/1.40 Oil DIC M27 
objective and Carl Zeiss ZEN Blue edition software.
High- vs. Low-MBL UCS and NHS Pools
Complement activation on A. fumigatus was evaluated in normal 
and umbilical cord serum (UCS) samples divided into pools 
according to their relative MBL levels based on measurements 
from a sandwich ELISA assay (HYB 131-1/HYB 131-1*). Four 
serum pools were prepared: (I) “high-MBL” NHS (eight donors), 
(II) “high-MBL” UCS (eight donors), (III) “low-MBL” NHS 
(seven donors), and (IV) “low-MBL” UCS (seven donors). The 
MBL concentrations in the “low-MBL” pools were ~0.4 μg/ml 
and the “high-MBL” pools ~2 μg/ml. Each of the serum pools 
were diluted in barbital buffer and binding of IgG (1% serum) 
and IgM (5% serum) as well as deposition of C3b (10% serum) 
were measured in flow cytometry using these Ab combinations: 
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anti-IgG pAb/goat anti-rabbit-FITC pAb; anti-IgM pAb/goat 
anti-rabbit-FITC pAb; anti-C3c pAb/goat anti-rabbit-FITC pAb; 
and rabbit IgG isotype/goat anti-rabbit-FITC pAb.
c3b and MBl correlation in Ucs
The correlation between the two following parameters was evalu-
ated: MBL concentrations in 23 umbilical cord EDTA plasma 
samples measured in ELISA (HYB 131-1/HYB 131-1*) and 
deposition of C3b on A. fumigatus measured in flow cytometry 
(as previously described).
MBl and c1q inhibition in nhs vs. Ucs
An UCS pool (21 samples) and the NHS pool were mixed with the 
MBL inhibitor (5 μg/ml 3F8) or C1q-inhibitor (10 μg/ml CLB/
C1q85) and mock-inhibitors (5 μg/ml 1C10 or 10 μg/ml mouse 
IgG1). The effect on complement activation was assessed by flow 
cytometry using barbital buffer as dilution buffer.
immunoglobulin insufficiency
Serum samples were obtained from three patients with differ-
ent immunological disorders: (I) IgA deficiency, (II) X-linked 
agammaglobulinemia (in IgG replacement therapy), and (III) 
common variable immunodeficiency (see Table 1). Samples were 
combined with MBL inhibitor (5 μg/ml 3F8) or C1q-inhibitor 
(10 μg/ml CLB/C1q85) and mock-inhibitors (5 μg/ml 1C10 or 
10 μg/ml mouse IgG1), and the percent difference in C3b between 
inhibitor and mock-inhibitor treated serum was calculated from 
the flow cytometric MFI values.
statistics
Statistical analyses were performed with GraphPad Prism 6 
(GraphPad Software, San Diego, CA, USA). The results represent 
the means ±  SD of three independent experiments. For two-
condition comparisons we used two-tailed Student’s t-test and 
for more than two conditions we used one-way ANOVA with 
Bonferroni’s multiple comparison correction. Correlation studies 
were evaluated using Spearman’s rank correlation. p-Values and 
multiplicity adjusted p-values: ns p > 0.05; *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001.
ethical approval
The study was approved by the regional Health Ethics Committee 
in the Capital Region of Denmark (reference no. H2-2011-133).
resUlTs
Binding of native MBl, Ficolin-2, and c1q 
to A. fumigatus with/without specific 
inhibitors
Based on initial experiments, screening the complement PRMs 
C1q, MBL, ficolin-1, ficolin-2, and ficolin-3 for their ability to 
bind A. fumigatus (Figure S1 in Supplementary Material), the 
following PRMs were chosen as candidates for further studies: 
ficolin-2, MBL, and C1q. We confirmed the binding by incubating 
A. fumigatus with NHS followed by analyses of the A. fumigatus 
eluates with SDS-PAGE and Western blotting. Figures  1A–C 
shows the presence of ficolin-2, MBL, and C1q in the eluates (lane 
2). We furthermore verified the efficacy of three specific inhibi-
tory Abs targeting the PRM binding sites (lane 3) and proved the 
specificity using mock-inhibitory Abs as controls (lane 4).
alternative Pathway amplification – not 
initiation
The effect of alternative pathway on A. fumigatus was examined 
by combining A. fumigatus and NHS under two conditions: 
calcium-sufficient or both calcium- and magnesium-sufficient. 
The results clearly showed that magnesium amplified C3b 
and TCC, suggesting an alternative pathway-driven response 
(Figures 2A,B).
Next, we excluded the influence of classical and lectin 
pathway by measuring complement activation in human 
C2-deficient serum, naturally lacking the capacity to form 
classical/lectin pathway C3 convertase (C4b2a), and found that 
complement could not be activated without reconstituting C2 
(Figures 2C,D).
We then examined the complement response in NHS under 
magnesium-sufficient/calcium-deficient conditions (Mg2+/
EGTA). We found that NHS diluted in Mg2+/EGTA facilitated 
the same levels of C3b and TCC as in EDTA, i.e., no downstream 
activation occurred when the classical and lectin pathways were 
excluded (Figures 2E,F). Increasing the serum concentration to 
40% did not enable activation of the alternative pathway in Mg2+/
EGTA either (Figure 3). Thus, taken together, Figures 2C–F and 
3 shows that classical and/or lectin pathways are a prerequisite for 
complement initiation on A. fumigatus.
complement activation in MBl- and  
c1q-Deficient serum
To distinguish between the contribution from the classical 
and the lectin pathways to complement activation, we tested 
the effect of reconstituting C1q- and MBL-deficient serum. 
By omitting  magnesium in the dilution buffer, we excluded 
alternative pathway interference and focused on the two other 
pathways. Reconstitution of C1q-deficient serum significantly 
increased C4b, C3b, and TCC (Figures 4A–C). On the contrary, 
reconstitution of MBL-deficient serum did not affect activation 
of complement except for a non-significant increase in C4b 
deposition (Figures 4D–F). These results imply that the classical 
pathway is the dominant complement initiator in response to 
A. fumigatus.
MBl and Ficolin-2 inhibition in  
c1q-Deficient serum
Next, we investigated the process of complement activation in 
the absence of the classical pathway. For this purpose, we applied 
C1q-deficient serum in combination with two lectin pathway 
inhibitors targeting MBL and ficolin-2. We found that comple-
ment was still activated in C1q-deficient serum and interestingly, 
inhibition of MBL and not ficolin-2 reduced C4b and C3b deposi-
tion on A. fumigatus (Figures 5A,B). We also observed a drop 
FigUre 1 | Binding of native MBl, ficolin-2, and c1q to A. fumigatus. A. fumigatus conidia were incubated in NHS with ficolin-2, MBL, or C1q-inhibitor/
mock-inhibitors, and eluates of the bound proteins were examined using SDS-PAGE and western blotting. (a) Ficolin-2, (B) MBL, and (c) C1q. Lane 1: purified 
rficolin-2, rMBL, and C1q. Lane 2: protein captured by A. fumigatus in NHS. Lane 3: captured protein in the presence of an inhibitor. Lane 4: captured protein in the 
presence of a mock-inhibitor.
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in TCC, although not statistically significant (Figure 5C). Thus, 
MBL drives the activation of complement under conditions with 
a dysfunctional classical pathway.
MBl-Mediated Opsonophagocytosis
A crucial function of complement is to facilitate phagocytosis. 
Therefore, we tested whether the MBL-driven complement 
activation in C1q-deficient serum had an impact on the neu-
trophilic uptake of A. fumigatus. FITC-conjugated conidia 
were opsonized with C1q-deficient serum mixed with the MBL 
inhibitor, and afterward phagocytosis by isolated human neu-
trophils was assessed. We found that the opsonization potential 
of C1q-deficient serum decreased as a result of MBL inhibition 
(Figure  6); both the percentage of phagocytizing neutrophils 
and the phagocytic index (the amount of conidia per neutrophil) 
were significantly reduced upon MBL inhibition (Figures 6A,B). 
Figure 6C presents a visual impression of the phagocytic process 
shown with fluorescence and differential interference contrast 
(DIC) imaging.
The role of MBl in Umbilical cord serum
We have shown that MBL is an important complement activator 
in C1q-deficient serum. Our next step was to explore the role 
of MBL when classical pathway function was compromised due 
to immunoglobulin insufficiency. Based on MBL serum levels, 
NHS and UCS samples were divided into serum pools contain-
ing either low-MBL levels (~0.4 μg/ml) or high MBL (~2 μg/
ml) (Figure S2 in Supplementary Material). The two NHS pools 
facilitated both IgG and IgM binding, whereas the UCS pools 
facilitated IgG but not IgM binding (Figures 7A–D). “High-MBL” 
UCS and NHS showed equivalent levels of deposited C3b, but 
“low-MBL” UCS mediated significantly less C3b than “low-MBL” 
NHS (Figures  7E,F). Thus, despite significant IgG binding in 
UCS, the absence of IgM appeared to affect the classical pathway 
FigUre 3 | alternative pathway-mediated complement activation on 
A. fumigatus in 40% normal human serum. C3b deposition was 
measured on A. fumigatus (1 × 107 conidia/ml) after incubation in 10 and 
40% NHS under following conditions: barbital buffer, 10 mM Mg/EGTA, and 
10 mM EDTA. C3b deposition was measured by flow cytometry and 
expressed as mean fluorescence intensity (MFI). Results represent the means 
of three independent experiments ± SD, *p ≤ 0.05 (one-way ANOVA, 
Bonferroni’s multiple comparison test).
FigUre 2 | alternative pathway-mediated complement amplification 
on A. fumigatus. Complement activation was measured on A. fumigatus 
(1 × 107 conidia/ml) after incubation in various buffers and sera. (a,B) 
NHS-generated C3b and TCC with/without Mg2+ in the dilution buffer. (c,D) 
C3b and TCC from C2-deficient serum with/without reconstitution of C2 
(e,F) NHS-generated C3b and TCC under Mg2+/EGTA and EDTA conditions. 
Complement products were measured by flow cytometry and expressed as 
mean fluorescence intensity (MFI). Results represent the means of three 
independent experiments ± SD, *p ≤ 0.05, **p ≤ 0.01 (two-tailed paired 
Student’s t-test or one-way ANOVA, Bonferroni’s multiple comparison test).
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to an extent that made MBL the central complement activator on 
A. fumigatus. These results were supported by the existence of a 
strong positive correlation between MBL levels and C3b deposi-
tion in UCS (Figure 8).
c1q and MBl inhibition in normal and 
Umbilical cord serum
To further differentiate C1q and MBL as complement activa-
tors on A. fumigatus, we compared the effect of C1q and MBL 
inhibition in NHS and UCS. C1q inhibition significantly reduced 
C3b deposition in NHS, while MBL inhibition had no effect 
(Figure 9A). There was a similar pattern regarding the formation 
of TCC (Figure 9B). In UCS, however, MBL inhibition reduced 
complement activation two to three times more than C1q inhibi-
tion (Figures 9C,D).
c1q and MBl inhibition in serum from 
immunocompromised Patients
The results presented up to this point were generated using model 
systems with C1q-deficient serum and UCS to explore the possible 
behavior of complement in patients with a low supply of anti-A. 
fumigatus Abs. As a continuation, we tested whether the proposed 
role of MBL as the main activator under such conditions was appli-
cable to a more authentic model. For this purpose, we used sera from 
three patients suffering from different immune disorders. Table 1 
shows the diagnosis and immunoglobulin levels as reported in the 
clinical records. In addition the table shows our measurements of 
the binding of IgG and IgM to A. fumigatus; we assigned the meas-
urements with ratings from – to +++, according to a comparison 
with the binding levels observed in the previously applied NHS 
pool. These measurements, combined with the reduction in C3b 
caused by C1q or MBL inhibition, provided the following informa-
tion: MBL-initiated activation accounted for approximately 70% of 
the total complement activation in the samples with low IgG/IgM 
binding (61 and 75%), whereas the sample with abundant IgG/IgM 
binding mainly activated complement via C1q (67%). Again IgM 
seemed to play a central role as the patient with no IgM binding 
(X-linked agammaglobulinemia) had low classical pathway activity 
despite measurable IgG binding (together C1q and MBL inhibition 
did not add up to 100% as they were not applied simultaneously 
and possibly due to the alternative pathway amplification).
FigUre 4 | reconstitution of c1q- and MBl-deficient sera. A. fumigatus (1 × 107 conidia/ml) was added into (a–c) C1q- or (D–F) MBL-deficient serum 
diluted in TBS/Ca2+ (no Mg2+). Complement products were measured by flow cytometry and expressed as mean fluorescence intensity (MFI): (a,D) C4b, (B,e) C3b, 
and (c,F) TCC. Results represent the means of three independent experiments ± SD, *p ≤ 0.05, ****p ≤ 0.0001 (two-tailed paired Student’s t-test).
FigUre 5 | MBl-mediated complement activation in the absence of 
the classical pathway. A. fumigatus (1 × 107 conidia/ml) was added into 
C1q-deficient serum plus ficolin-2 inhibitor, MBL inhibitor, or MBL mock-
inhibitor. Complement products were measured by flow cytometry and 
expressed as mean fluorescence intensity (MFI): (a) C4b, (B) C3b, and (c) 
TCC. Results represent the means of three independent experiments ± SD, 
*p ≤ 0.05 (one-way ANOVA, Bonferroni’s multiple comparison test).
FigUre 6 | MBl-mediated opsonophagocytosis of A. fumigatus in 
c1q-deficient serum. FITC-conjugated A. fumigatus conidia 
(1 × 107 conidia/ml) were opsonized with C1q-deficient serum including MBL 
inhibitor or MBL mock-inhibitor. Opsonized conidia were mixed with isolated 
human neutrophils in a ratio of 5:1, and phagocytosis was quantified by flow 
cytometry. (a) The percentage of phagocytizing neutrophils. (B) Phagocytic 
index (percentage of phagocytizing neutrophils × MFI). (c) Fluorescence and 
DIC microscopy image of neutrophils phagocytizing A. fumigatus-FITC. 
Results represent the means of three independent experiments ± SD, 
*p ≤ 0.05 (two-tailed Student’s t-test). MFI = mean fluorescence intensity.
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DiscUssiOn
Complement is a crucial part of the innate immune system and 
has been shown to participate in the defense against A. fumiga-
tus (12), but the roles of the three complement pathways have 
never been fully established. Through in  vitro experiments, we 
approached this query from two angles – the immunocompetent 
and the immunocompromised situation – as we found this 
FigUre 9 | inhibition of MBl in umbilical cord serum. A. fumigatus 
(1 × 107 conidia/ml) was applied into (a,B) NHS (c,D) UCS to estimate the 
effect of C1q and MBL inhibition. Complement products were measured by 
flow cytometry and expressed as mean fluorescence intensity (MFI). Results 
represent the means of three independent experiments ± SD, *p ≤ 0.05. 
**p ≤ 0.01 (one-way ANOVA, Bonferroni’s multiple comparison test).
FigUre 8 | correlation between MBl and c3b in umbilical cord 
serum. A. fumigatus (1 × 107 conidia/ml) was added into UCS samples, and 
C3b deposition was measured using flow cytometry. MBL levels were 
measured in the same samples using a single-epitope sandwich ELISA. The 
two factors – C3b and MBL – were positively correlated (spearman 
rank = 0.75, p < 0.0001, n = 23). C3b is expressed as mean fluorescence 
intensity (MFI) and represent the mean of three independent experiments. 
MBL measurements were performed in triplicates and are presented in 
micrograms per milliliter.
FigUre 7 | MBl-mediated complement activation in the absence of 
igM binding. NHS and UCS pools with “high” and “low” contents of MBL 
were mixed with A. fumigatus (1 × 107 conidia/ml) to determine the following 
components: (a,B) IgG binding, (c,D) IgM binding, (e) C3b generated from 
“high-MBL” NHS and “high-MBL” UCS, and (F) C3b generated from 
“low-MBL” UCS and “low-MBL” NHS. Deposited C3b and bound IgG/IgM 
were measured by flow cytometry and expressed as mean fluorescence 
intensity (MFI). Results represent the means of three independent 
experiments ± SD, ****p ≤ 0.0001 (unpaired Student’s t-test).
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particularly important for studying an opportunistic pathogen 
like A. fumigatus.
Initially, we established that alternative pathway overall 
strongly boosted complement activation on resting A. fumigatus 
conidia. The importance of alternative pathway on A. fumigatus 
was already described in studies made 30–40 years ago (13, 14), 
but as opposed to those observations we did not find alternative 
pathway capable of initiating the cascade. In our hands, classi-
cal and/or lectin pathway were needed to generate the first C3 
convertases, which we demonstrated using Mg/EGTA on normal 
serum, thereby excluding the lectin and classical pathways, and 
by using C2-deficient serum. This is also in contradiction to 
the previously reported C2-bypass mechanism of activation on 
A. fumigatus (15). This might be explained by differences between 
A. fumigatus strains, an issue that could have been addressed by 
incorporating multiple strains; however, this was beyond the 
scope of the present study.
Previously, MBL (16), ficolin-2 (17), and C1q (18) have been 
shown to bind A. fumigatus, which we confirmed in NHS. As we 
progressed to characterize the complement initiation process, we 
found C1q to be the main conductor of activation, while MBL 
and ficolin-2 did not contribute significantly. Recently, another 
in  vitro study reached a similar conclusion showing that C1q-
mediated complement activation led to neutrophilic phagocytosis 
of A. fumigatus (19), which underlines classical pathway as the 
TaBle 1 | c1q and MBl inhibition in sera from immunocompromised patients.
Diagnosis Treatment igg/igM/iga (g/l) Bound igg/igM c3b after MBl inhibition (%) c3b after c1q inhibition (%)
IgA deficiency No 16.2/0.6/<0.05 +++/+++ ↑3 ↓67
X-linked agammaglobulinemia IgG therapy 10.3/<0.05/<0.05 ++/− ↓61 ↓18
Common variable immunodeficiency No 2.6/<0.05/<0.05 +/+ ↓75 ↓7
A. fumigatus (1 × 107 conidia/ml) was incubated with sera from three patients with different immune disorders. Bound IgG and IgM were compared and rated relative to an NHS 
pool: >100%: +++; 50–100%: ++; <50%: +; 0%: −. The effect of C1q and MBL inhibition was evaluated based on the C3b deposition. The results show the mean% reduction 
in C3b deposition caused by the inhibitor [(1 − C3b with inhibitor/C3b with mock-inhibitor)%]. Serum levels of IgG, IgM, and IgA were obtained from the clinical records, and 
calculations of bound IgG/IgM and C3b were based on flow cytometric mean fluorescence intensity values. Inhibition experiments represent the means of three independent 
experiments. Downward-pointing arrows indicate a C3b reduction and upward-pointing arrows a C3b increase.
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likely route of complement activation under normal immuno-
competent conditions.
This situation, however, is different from the medical 
background of most IPA patients; hence, we wanted to mimic 
the limitation of Abs that exists as a secondary complication 
in many immunocompromised patients. Classical pathway 
would probably be disadvantaged by a low antibody content, 
which made C1q-deficient serum a relevant matrix to study. 
We found that MBL (but not ficolin-2) was able to activate 
complement on behalf of C1q and furthermore able to mediate 
opsonophagocytosis.
The next step was to simulate the actual inadequacy of Abs, 
which we pursued in serum from umbilical cords. We found 
that UCS did not facilitate any IgM binding to A. fumigatus and 
that a pool of UCS with a low-MBL content had substantially 
decreased complement activation – a relation not seen in NHS 
with low-MBL content. The clear positive correlation between 
MBL levels and C3b deposition in UCS supported this observa-
tion. It is noteworthy that IgM predicted the outcome of classical 
pathway activity since IgG binding from UCS did not resurrect 
the pathway. We made a similar observation in serum from 
an X-linked agammaglobulinemic patient in IgG replacement 
therapy (IVIG); despite IgG binding to A. fumigatus, the absence 
of IgM positioned MBL as the main complement activator instead 
of C1q. Unfortunately, only three immunoglobulin-insufficient 
patients were eligible for this investigation. Therefore, conclu-
sions based on these experiments alone should be considered 
with some caution, but collectively the UCS samples and the 
patient samples give a good indication of the general complement 
mechanisms in a compromised immune system.
A clinical study showed that IPA patients had lower concentra-
tions of MBL in their serum compared to febrile immunocom-
promised controls and that there was a higher frequency of MBL 
deficiency among the IPA patients (20). Other clinical studies 
have shown that patients with chronic forms of pulmonary 
aspergillosis have lower levels of high-order oligomeric MBL 
(21, 22). Our findings could very well explain the outcome of 
these different clinical studies and substantiate MBL as a possible 
future drug-component for treatment and prophylaxis against 
A. fumigatus.
As a proof of concept, it has been shown that corticosteroid-
immunosuppressed mice infected with A. fumigatus had an 
enhanced chance of survival after MBL-treatment (23). In this 
context, it is important to mention another study showing that 
non-immunosuppressed MBL-knockout mice were less suscep-
tible to systemic A. fumigatus infection compared to wild-type 
mice (24). It was suggested (not shown) by the authors that the 
wild types did not die due to A. fumigatus, but from neutrophilic 
infiltration causing detrimental tissue-damage. Nevertheless, 
it shows that MBL is a double-edged sword, and care must be 
taken in potential future MBL-treatment. For the time being, 
MBL screenings could possibly be a useful tool in the clinic to 
evaluate the risk of A. fumigatus infection in immunocompro-
mised patients, especially considering that around 10% of the 
Caucasian population carries gene variants that cause different 
MBL-deficient states (25).
Finally, our findings also suggest IgM-replacement therapy as 
another treatment option, since classical pathway seemed to be 
highly dependent on IgM to initiate complement on A. fumigatus. 
IgM-enriched intravenous IgG (IVIG) has been shown to pos-
sibly benefit patients with Gram-negative septic shock (26) and 
perhaps this applies to IPA patients as well.
cOnclUsiOn
In a competent immune system, A. fumigatus conidia are 
eliminated before an invasion of the pulmonary tissue can 
occur. However, in the absence of a well-functioning defense, 
A. fumigatus can cause severe infections and ultimately death. 
C1q appears to activate complement on A. fumigatus in the 
immunocompetent state, but many immunocompromised 
patients have low antibody levels and according to our findings 
this seems to position MBL as the key activator of complement 
instead of C1q. Possibly this explains why clinical studies have 
shown that low-MBL levels are a risk factor of A. fumigatus 
infections. With this study, we contribute to a deeper insight 
into the mechanisms of how complement combats A. fumigatus 
infections under healthy and especially immunocompromised 
circumstances.
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